C12N 2310/333
Modified a
Official title: Modified A
C12N2310/333 (Modified a) appears on 189 US grants and 211 published applications in this corpus.
Search patents in C12N- Granted patents
- 189
- Published applications
- 211
- Assignees
- 118
- Inventors
- 448
- Latest grant
- 24 Feb 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1993 | 1 | 0 |
| 1994 | 1 | 0 |
| 1995 | 2 | 0 |
| 1996 | 11 | 0 |
| 1997 | 19 | 0 |
| 1998 | 14 | 0 |
| 1999 | 11 | 0 |
| 2000 | 10 | 0 |
| 2001 | 4 | 2 |
| 2002 | 13 | 3 |
| 2003 | 4 | 11 |
| 2004 | 3 | 6 |
| 2005 | 3 | 8 |
| 2006 | 4 | 6 |
| 2007 | 2 | 7 |
| 2008 | 0 | 1 |
| 2009 | 3 | 4 |
| 2010 | 6 | 8 |
| 2011 | 2 | 2 |
| 2012 | 7 | 3 |
| 2013 | 1 | 4 |
| 2014 | 2 | 6 |
| 2015 | 2 | 9 |
| 2016 | 1 | 5 |
| 2017 | 2 | 6 |
| 2018 | 3 | 11 |
| 2019 | 7 | 11 |
| 2020 | 7 | 16 |
| 2021 | 15 | 13 |
| 2022 | 10 | 11 |
| 2023 | 7 | 10 |
| 2024 | 6 | 9 |
| 2025 | 5 | 19 |
| 2026 | 1 | 20 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Methods and compositions for treatment of polycystic kidney disease24 Feb 2026US 12,559,750 B2Regulus Therapeutics Inc.
- SnRNA targeting USH2A pre-mRNA and application thereof16 Dec 2025US 12,497,617 B2Guangzhou Reforgene Medicine Co., Ltd.
- Compositions and methods for editing nucleic acids in cells utilizing oligonucleotides15 Jul 2025US 12,359,197 B2Etagen Pharma, Inc.
- Engineered guide RNA and uses thereof15 Apr 2025US 12,275,951 B2Ohio State Innovation Foundation
- Modified compounds and uses thereof25 Feb 2025US 12,234,447 B2Ionis Pharmaceuticals, Inc.
- Trem compositions and methods of use1 Oct 2026US 2026/0297575 A1Flagship Pioneering Innovations VI, LLC
- Antisense RNA (asRNA) Technology and Use Thereof24 Sep 2026US 2026/0286353 A11Globe Health Institute LLC
- Decoy rna oligonucleotides for inhibiting ythdf224 Sep 2026US 2026/0286355 A1Catchme Rna Therapeutics Ltd.
- Chemically modified antisense oligonucleotides for use in rna editing17 Sep 2026US 2026/0275338 A1ProQR Therapeutics II B.V.
- RNAi Agents for Inhibiting Expression of Superoxide Dismutase 1 (SOD1), Compositions Thereof, and Methods of Use17 Sep 2026US 2026/0275351 A1Arrowhead Pharmaceuticals, Inc.
Most cited
By later US patents
- N-2 substituted purines806US 5,459,255 AIsis Pharmaceuticals, Inc. · 1995
- Sugar modified oligonucleotides that detect and modulate gene expression641US 5,670,633 AIsis Pharmaceuticals, Inc. · 1997
- Oligonucleotides having phosphorothioate linkages of high chiral purity626US 5,587,361 AIsis Pharmaceuticals, Inc. · 1996
- Oligonucleotides containing N-2 substituted purines621US 5,587,469 AIsis Pharmaceuticals, Inc. · 1996
- Substituted purines and oligonucleotide cross-linking603US 5,681,941 AIsis Pharmaceuticals, Inc. · 1997